BIVI
BioVie Inc. (NASDAQ)
Healthcare — Biotechnology
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
Price History
Fundamentals
| Market Cap | $16.44M |
| P/E Ratio (TTM) | - |
| Forward P/E | -0.49 |
| EPS (TTM) | $-3.79 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -106.43% |
| Debt/Equity | 1.90 |
| Recommendation | None |
| Analyst Target | $5.00 |
| Analysts | 1 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 74.3 |
| Beta | 0.65 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $9.98 |
| 52-Week Low | $1.06 |
| 50-Day Avg | $1.61 |
| 200-Day Avg | $1.52 |
| Avg Volume | 123.4K |
| Volume | 388.5K |
Performance Analysis
NEUTRALBIVI presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 12:59 UTC
Back to Screener Export Report